
Jan 16 (Reuters) - U.S. private equity firm Hellman & Friedman is in early-stage talks for a potential sale of medical devices maker Cordis, seeking a value of over $9 billion, Bloomberg News reported on Friday, citing people familiar with the matter.
About half a dozen publicly traded medical device companies are currently evaluating potential bids for Cordis, the report added.
Hellman & Friedman bought Cordis from Cardinal Health in 2021 for about $1 billion, six years after Johnson & Johnson JNJ.N sold it.
Cordis is known for making cardiovascular devices such as catheters and stents.
H&F and KKR KKR.N, an investor in Cordis, declined to comment. Cordis did not immediately respond to Reuters' requests for comment outside of regular business hours.